Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters

Pfizer Inc PFE / BioNTech SE's BNTX omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process, BioNTech Chief Executive Ugur Sahin told Germany's Bild.

• Once the vaccine is ready, the company would assess whether it was still needed, Sahin said.
• Related: Pfizer's Omicron-Targeted Vaccine Expected To Be Ready In March: CEO Says On CNBC.
• "If the wave ends, that does not mean it can't begin again," he told Bild in a video interview.
• "I really don't see the situation as dramatic anymore," he said, referring to how the coronavirus would develop in the future.
• Related: Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial.
• Price Action: BNTX shares are down 4.16% at $158.61, PFE stock is down 1.34% at $49.02 during the market session on the last check Thursday.